DAPASIG 10

About

DAPASIG 10, containing dapagliflozin, is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus, heart failure, and chronic kidney disease. It works by inhibiting SGLT2 in the renal tubules, which reduces glucose reabsorption and increases glucose excretion in the urine, thereby lowering blood glucose levels. Beyond its glycemic control effects, dapagliflozin has demonstrated significant cardiovascular and renal protective benefits. It reduces the risk of cardiovascular death, hospitalization for heart failure, and the progression of kidney disease in relevant patient populations, often independent of its glucose-lowering effects. This makes it a valuable therapeutic option for patients with these co-morbidities. The 10mg dose is a common therapeutic strength for these indications.

Uses

• Treatment of type 2 diabetes mellitus.
• Reduction of risk of cardiovascular death and hospitalization for heart failure.
• Reduction of risk of sustained eGFR decline, end-stage kidney disease, or renal death.
• Adjunct to diet and exercise to improve glycemic control.

Directions For Use

Take orally once daily in the morning, with or without food, as prescribed by your doctor.

Benefits

• Lowers blood glucose levels.
• Reduces risk of heart failure hospitalization.
• Slows progression of chronic kidney disease.
• Promotes modest weight loss.
• Lowers blood pressure.
• Reduces risk of major adverse cardiovascular events.

Side Effects

• Genital mycotic infections (e.g., yeast infections)
• Urinary tract infections (UTIs)
• Increased urination
• Thirst
• Hypotension (low blood pressure)
• Diabetic ketoacidosis (rare, but serious)
• Kidney problems (acute kidney injury)
• Hypoglycemia (low blood sugar, especially with other diabetes meds)
• Back pain
• Nausea
• Dizziness
• Rash

Safety Measures

• Alcohol - Excessive alcohol intake may increase the risk of hypoglycemia or diabetic ketoacidosis; use with caution.
• Pregnancy - Not recommended during the second and third trimesters of pregnancy due to potential adverse renal effects on the fetus.
• Breastfeeding - Not recommended during breastfeeding as it may pass into breast milk and harm the infant.
• Liver - No dose adjustment is generally needed for mild to moderate hepatic impairment; use with caution in severe impairment.
• Kidney - Not recommended for initiation in patients with eGFR <25 mL/min/1.73m²; monitor kidney function before and during treatment.
• Lung - Generally safe for use in patients with lung conditions; no specific precautions are usually required.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.